|
Jul 18
|
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
|
|
Jul 17
|
Mirum Gains 35% in 3 Months: How Should You Play the Stock?
|
|
Jul 16
|
Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag
|
|
Jul 15
|
Arvinas Presents Promising Preclinical Data for BCL6 Degrader ARV-393 in Lymphoma Treatment
|
|
Jul 14
|
FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks
|
|
Jun 16
|
Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade
|
|
Jun 13
|
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress
|
|
Jun 5
|
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting
|
|
May 31
|
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
|
|
May 30
|
Does Arvinas (ARVN) Have the Potential to Rally 94.93% as Wall Street Analysts Expect?
|
|
May 30
|
Arvinas to Present at Jefferies Global Healthcare Conference
|
|
May 29
|
Pfizer and Arvinas gamble to shift breast cancer treatment paradigm
|
|
Apr 28
|
Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
|
|
Apr 28
|
Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting
|
|
Apr 23
|
Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
Apr 21
|
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting
|
|
Mar 27
|
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases
|
|
Mar 14
|
Biotech Alert: Searches spiking for these stocks today
|
|
Mar 14
|
The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
|
|
Mar 13
|
Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update
|